Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR Brachytherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

195 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Optimal non surgical treatment of prostate cancer requires dose escalation which is frequently provided by adding a brachytherapy "boost" to a short course of external beam radiotherapy. The hypothesis in this randomized study is that a High Dose Rate (HDR) brachytherapy boost leads to equivalent or better Prostate Specific Antigen (PSA) recurrence-free survival when compared to a Low Dose Rate (LDR) brachytherapy boost and that it is associated with a more favorable toxicity profile and improved quality of life.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

LDR vs. HDR Brachytherapy for Prostate Cancer

NCT03426748

Prostate Cancer

ACTIVE_NOT_RECRUITING NA

Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer

NCT02692105

Prostate Cancer

ACTIVE_NOT_RECRUITING PHASE3

Partial Prostate Salvage High Dose Rate Brachytherapy

NCT03246802

Recurrent Prostate Cancer

RECRUITING NA

Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer

NCT06200974

Localized Prostate Carcinoma

RECRUITING

HDR Brachytherapy vs. LDR Brachytherapy Monotherapy in Localized Prostate Cancer

NCT02628041

Prostate Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Men with intermediate or high risk prostate cancer who are technically suitable for prostate brachytherapy based on prostate size and voiding function and who are interested in this modality of treatment will be approached for randomization between either high dose rate (single 15 Gray) or low dose rate permanent seed implant (110 Gray) brachytherapy. Baseline International Prostate Symptom score, Quality of Life Assessment and International Index of Erectile Function will be recorded and then every 3 months for the first year and every 6 months to 3 years. Androgen deprivation treatment is allowed for 6 or 12 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LDR boost

After completion of 46 Gy of external beam radiotherapy subjects will undergo a permanent seed radioactive implant to the prostate using iodine-125 seeds to deliver a dose of 110 Gy

Group Type ACTIVE_COMPARATOR

LDR

Intervention Type RADIATION

Low dose rate brachytherapy boost

HDR boost

Subjects in this arm will undergo an HDR implant to deliver 15 Gy to the prostate prior to commencing the external beam component of their treatment.

Group Type ACTIVE_COMPARATOR

HDR

Intervention Type RADIATION

High dose rate brachytherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HDR

High dose rate brachytherapy

Intervention Type RADIATION

LDR

Low dose rate brachytherapy boost

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Upper tier intermediate risk with at least 2 of the following factors

1. Tumor-Nodes-Metastases Tumor stage T2B or greater
2. Gleason Score 7
3. PSA \> 10
4. \> 50% of the biopsies positive
* OR High risk prostate cancer with one of the following factors

1. T3a
2. Gleason Score8-10
3. PSA \>20
* Positive prostate biopsy within 12 months (reviewed centrally)
* International Prostate Symptom Score \< 16
* Prostate volume \< 60 cc
* Negative staging CT and Bone scan within 3 months prior to registration
* History and physical examination within 90 days prior to registration
* European Cooperative Oncology Group performance status 0-1 prior to registration
* Age \>45
* Patient suitable for procedure under anesthesia

Exclusion Criteria

* Prior invasive malignancy (except non melanoma skin cancer) unless disease-free for at least 3 years prior to registration
* Previous prostatectomy, cryotherapy or High Intensity Focussed Ultrasound for prostate cancer
* Previous pelvic irradiation or prostate brachytherapy

Minimum Eligible Age

45 Years

Maximum Eligible Age

80 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No